Shaping the Next Era of Cardiac Ablation: Clinical Insights From Early Adopters
Real-world perspectives from PulseSelect™ and Affera™
With lots of new pulsed-field ablation (PFA) technology becoming available, one key question emerges: How are these systems performing in real-world clinical practice? This on-demand version of the session takes you inside the lab to share practical perspectives from physicians at the forefront of PFA adoption.
Chaired by Dr Jack McCready (University Hospitals Sussex NHS Foundation Trust, UK), the session features insightful presentations and discussions with Dr Richard Balasubramaniam (Royal Bournemouth Hospital, UK) and Dr Sandeep Panikker (University Hospital Coventry, UK) as they explore the next era of cardiac pulsed-field ablation (PFA).
Dr Panikker presents his experience with the PulseSelect™ PFA system, a technology setting a new standard in safety for paroxysmal and persistent atrial fibrillation ablation, supported by 15 years of robust preclinical and clinical evidence.1
Following this, Dr Balasubramaniam shares real-world insights from using the Affera mapping and ablation system. The Affera Sphere-9™ introduces an all-in-one solution that combines high-resolution mapping with dual-energy ablation, enabling electrophysiologists to seamlessly transition between pulsed-field and radiofrequency modalities within a single system.
Catch up on the session at your convenience, to see how PFA systems can be integrated into everyday clinical workflows and explore how these technologies are reshaping efficiency, safety, and outcomes in cardiac ablation.
Excerpts from the session
'PFA of course is a novel technology and it offers potential advantages over our current thermal ablation in terms of safety…Certainly, the ablation delivery is very much quicker' - Dr Sandeep Panikker
'We found [Affera Sphere-9] to be quick, safe, effective, and really very easy to use…It is consistent, so you can book cases and not feel that one’s going to take forever. This catheter is so versatile that when something turns up, you feel able to tackle that as well…' - Dr Richard Balasubramaniam
Key Learning Objectives
- To understand that PulseSelect offers the safest PFA with the most durable lesions
- To appreciate that Affera redefines all-in-one mapping and dual energy ablation
- To learn from real-world examples of how to integrate these technologies into clinical practice, and absorb best practices and recommendations
Target Audience
- Consultant Cardiologists
- Electrophysiologists
- Cardiac Nurses
- Cardiac Physiologists
- Healthcare Managers
More from this programme
Part 1
Introduction
Dr Jack McCready introduces the webinar and shares an overview of his personal experience of PFA at his centre.
| 1 session | |
| Introduction | Watch now |
Part 2
Pulseselect™ - Real-World Case And Learnings From Coventry
Dr Panikker presents his experience with the PulseSelect™ PFA system, a technology setting a new standard in safety for paroxysmal and persistent atrial fibrillation ablation.
Part 3
Affera Sphere-9™ - Real-World Case And Learnings From Bournemouth
Dr Balasubramaniam shares real-world insights from using the Affera mapping and ablation system.
Part 4
Q&A and Panel Discussion
Dr Jack McCready chairs an engaging panel discussion with the faculty, answering questions from the audience.
| 1 session | |
| Q&A and Panel Discussion | Watch now |
Faculty Biographies
Richard Balasubramaniam
Consultant Cardiologist & EP, and Clinical Lead for Cardiac Rhythm Management at University Hospitals Dorset
Dr Richard Balasubramaniam is a Consultant Cardiologist & EP, and Clinical Lead for Cardiac Rhythm Management at University Hospitals Dorset, UK.
Dr Balasubramaniam graduated from the University of Birmingham in 1996, having been a winner of the Aesculapius Prize for services to medicine, and trained in Cardiology at Papworth Hospital, Cambridge before pursuing a fellowship in Electrophysiology under Professor Jonathan Kalman at the Royal Melbourne Hospital in Melbourne, Australia, one of the world’s leading centres in cardiac electrophysiology. During the training, he completed a PhD at Cambridge University in ventricular arrhythmias in genetically modified murine models of arrhythmogenesis and maintained an interest in the management of patients with channelopathies and aborted sudden cardiac death. He was appointed as a Consultant Cardiologist and Electrophysiologist at the Royal Bournemouth Hospital in December 2008.
Comments